Acadia Pharmaceuticals | ACAD - Operating Expenses


Acadia Pharmaceuticals reported $270.12M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
ALKERMES USD 1.81B 57.02M Jun/2026
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
Biogen USD 2.98B 1.02B Jun/2026
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Cara Therapeutics USD 7.05M 1.11M Mar/2026
Corcept Therapeutics USD 214.85M 343K Jun/2026
Cytokinetics USD 207.8M 7.22M Jun/2026
Eisai JPY 209.6B 6.14B Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Incyte USD 973.64M 4.65B Jun/2026
J&J USD 17.83B 388M Jun/2026
Moderna USD 960M 817M Jun/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Prothena USD 25.29M 1.94M Mar/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026